or Try an Advanced Search...

    ETF Components for ARKG - ARK Genomic Revolution Multi-Sector ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    CRSP F 1.08 7.23
    TWST D -0.74 6.08
    EXAS B 0.41 5.67
    RXRX F -0.94 5.36
    SDGR F -2.80 4.55
    NTLA F -0.84 3.97
    TXG F -0.72 3.92
    IONS D -0.24 3.92
    BEAM F 0.00 3.87
    DNA F 6.08 3.67
    ARCT F -4.78 3.65
    CDNA F -2.54 3.54
    TDOC F 0.30 3.22
    ACCD D 5.40 3.21
    NRIX A 2.56 2.99
    MRNA A -1.39 2.76
    VCYT F 1.80 2.69
    PACB F 4.29 2.63
    VEEV D 0.17 2.61
    VRTX C 0.10 2.38
    ADPT F -4.30 1.83
    MASS F 0.18 1.72
    VERV F -1.19 1.61
    QSI F -1.31 1.53
    INCY F 0.19 1.49
    ABSI B -6.05 1.32
    CMPS F -1.29 1.31
    PATH F -0.42 1.19
    PRME F -6.90 1.17
    REGN C -0.80 1.10
    AMGN D -0.50 0.92
    CERS F 0.00 0.92
    RPTX F -5.92 0.70
    BFLY F 0.07 0.70
    PSNL F 0.83 0.57
    NTRA A -3.38 0.53
    GH F 1.71 0.44
    NVDA A 0.76 0.22

    Represented by ETF Holdings

    Keywords: Biotechnology Cancer Biopharmaceutical Drug Discovery Life Sciences Biology Medicine Nasdaq 100 S&P 500 Genetics Genomics Telehealth Telemedicine Molecular Biology Precision Medicine Acid Artificial Intelligence Blood Test Breakthrough Therapy CRISPR
    Industries: Biotechnology Diagnostics & Research Health Information Services Health Information Services Medical Devices Drug Manufacturers - Major Medical Care Facilities Semiconductors Software - Infrastructure

    Recent News for ARK Genomic Revolution Multi-Sector ETF & its Holdings

    Date Stock Title
    Apr 19 NVDA Buying The Dip? Jim Cramer And Tom Lee Warn Market Hasn't Hit Rock Bottom Yet: 'Quintessential Wrong Thing To Do'
    Apr 18 NVDA Dow Jones Futures: Stock Market Power Trend On Cusp Of Ending; Netflix Subscribers Jump
    Apr 18 NVDA What Are GenZ's Favorite Stocks?
    Apr 18 GH Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
    Apr 18 QSI Quantum-Si to Report First Quarter 2024 Financial Results on May 9, 2024
    Apr 18 NVDA If Rates Stay Higher for Longer, Buy Tech Stocks and Value
    Apr 18 REGN Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
    Apr 18 NVDA Why Is Broadcom Stock a Winner? It’s the Difference Between Nvidia and Apple.
    Apr 18 NVDA Nvidia: Everything to know about the chipmaking powerhouse
    Apr 18 NVDA Top Stock Reports for NVIDIA, Alphabet & Johnson & Johnson
    Apr 18 VEEV How Is The Market Feeling About Veeva Systems?
    Apr 18 NVDA Chip sector correction is 'a cautious blow': Analyst
    Apr 18 ARKG ARK Launches European Innovation, Genomics ETFs
    Apr 18 NVDA Is This the Reason AMD, Nvidia, and Intel Stocks Dropped?
    Apr 18 NVDA Chip sector enters correction territory on demand concerns
    Apr 18 NVDA Stock Market Today: Dow Jones Up As Nvidia Tests Key Level, Taiwan Semiconductor Triggers Sell Rule
    Apr 18 NVDA Forget Tesla. Top Funds Love This Non-Mag 7 AI Giant.
    Apr 18 NVDA Cognizant (CTSH) Launches Fraud Prevention Solution With FICO
    Apr 18 NVDA Nvidia Stock Is Wavering. What Taiwan Semi’s Earnings Mean for the Chip Maker.
    Apr 18 TDOC Analysts Estimate Teladoc (TDOC) to Report a Decline in Earnings: What to Look Out for
    Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
    Exchange Traded Fund ETF Biotechnology Stem Cell Genomics Bioinformatics
    Back to the Main ARKG Page...